Low doses of colistimethate

don’t rush in!

Alexandre P Zavascki, Roger L Nation

Research output: Contribution to journalComment / DebateOtherpeer-review

Abstract

To the Editor—Bennatar et al compared clinical outcomes between so called high-dose and low-dose regimens of intravenous colistimethate [1]. Although 28-day mortality tended to be lower for high-dose than for low-dose regimens (34.7% vs 42.9%, respectively;P = .09), they found no significant difference either after adjustment in a multivariate model or after matching patients by a propensity score. Beyond the limitations addressed in the editorial commentary by Pogue et al [2], we believe there are other critical aspects that may have favored the null hypothesis.
Original languageEnglish
Pages (from-to)695-696
Number of pages2
JournalClinical Infectious Diseases
Volume64
Issue number5
DOIs
Publication statusPublished - 2017

Cite this

Zavascki, Alexandre P ; Nation, Roger L. / Low doses of colistimethate : don’t rush in!. In: Clinical Infectious Diseases. 2017 ; Vol. 64, No. 5. pp. 695-696.
@article{453ce73a22634a9db7f79128a267c7f2,
title = "Low doses of colistimethate: don’t rush in!",
abstract = "To the Editor—Bennatar et al compared clinical outcomes between so called high-dose and low-dose regimens of intravenous colistimethate [1]. Although 28-day mortality tended to be lower for high-dose than for low-dose regimens (34.7{\%} vs 42.9{\%}, respectively;P = .09), they found no significant difference either after adjustment in a multivariate model or after matching patients by a propensity score. Beyond the limitations addressed in the editorial commentary by Pogue et al [2], we believe there are other critical aspects that may have favored the null hypothesis.",
author = "Zavascki, {Alexandre P} and Nation, {Roger L}",
year = "2017",
doi = "10.1093/cid/ciw807",
language = "English",
volume = "64",
pages = "695--696",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",

}

Low doses of colistimethate : don’t rush in! / Zavascki, Alexandre P; Nation, Roger L.

In: Clinical Infectious Diseases, Vol. 64, No. 5, 2017, p. 695-696.

Research output: Contribution to journalComment / DebateOtherpeer-review

TY - JOUR

T1 - Low doses of colistimethate

T2 - don’t rush in!

AU - Zavascki, Alexandre P

AU - Nation, Roger L

PY - 2017

Y1 - 2017

N2 - To the Editor—Bennatar et al compared clinical outcomes between so called high-dose and low-dose regimens of intravenous colistimethate [1]. Although 28-day mortality tended to be lower for high-dose than for low-dose regimens (34.7% vs 42.9%, respectively;P = .09), they found no significant difference either after adjustment in a multivariate model or after matching patients by a propensity score. Beyond the limitations addressed in the editorial commentary by Pogue et al [2], we believe there are other critical aspects that may have favored the null hypothesis.

AB - To the Editor—Bennatar et al compared clinical outcomes between so called high-dose and low-dose regimens of intravenous colistimethate [1]. Although 28-day mortality tended to be lower for high-dose than for low-dose regimens (34.7% vs 42.9%, respectively;P = .09), they found no significant difference either after adjustment in a multivariate model or after matching patients by a propensity score. Beyond the limitations addressed in the editorial commentary by Pogue et al [2], we believe there are other critical aspects that may have favored the null hypothesis.

U2 - 10.1093/cid/ciw807

DO - 10.1093/cid/ciw807

M3 - Comment / Debate

VL - 64

SP - 695

EP - 696

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 5

ER -